Title: Day Hospital Mentalization-Based Treatment (MBT-DH) versus treatment-as-usual in the treatment of severe borderline personality disorder: Protocol of a randomized controlled trial.

Authors:

Elisabeth M.P. Laurensssen (annelies.laurensssen@deviersprong.nl)
Dieuwertje Westra (dieuwertje.westra@deviersprong.nl)
Martijn J. Kikkert (martijn.kikkert@arkin.nl)
Marc J. Noom (marc.noom@deviersprong.nl)
Hester V. Eeren (h.vaneeren1@erasmusmc.nl)
Anna J. van Broekhuyzen (anne.van.broekhuyzen@deviersprong.nl)
Jaap Peen (jaap.peen@arkin.nl)
Patrick Luyten (patrick.luyten@ppw.kuleuven.be)
Jan J.V. Busschbach (jan.busschbach@deviersprong.nl)
Jack J.M. Dekker (jack.dekker@arkin.nl)

Version: 3 Date: 6 May 2014

Author's response to reviews: see over
May 6th, 2014

Subject: Manuscript submission – revised version

Dear Dr. Rye Chua,

Hereby, I have the pleasure to send to you, on behalf of my co-authors, the revised version of the manuscript of “Day Hospital Mentalization-Based Treatment (MBT-DH) versus treatment-as-usual in the treatment of severe borderline personality disorder: Protocol of a randomized controlled trial”.

We sent the requested English translation of the METC declaration of Arkin and De Viersprong, combined in one document, to BMCSeriesEditorial@biomedcentral.com. Because GGZIngeest only had the intention to participate in the trial, there is no approval of participation from the METC for this site, so we left the site out of the article. The change made is shown below.

I am looking forward to hear from you again.

Yours sincerely, also on behalf of my co-authors,

Elisabeth

Viersprong Institute for Studies on Personality Disorders (VISPD)
P.O. Box 7
4660 AA Halsteren
The Netherlands
E-mail: annelies.laurensen@deviersprong.nl
Change made:

We took GGZingeest out of our article, because they only had the intention to participate in the trial, but never formally agreed nor did we ask the METC permission for participation of this side. So we changed the Design section on page 7 as follows:

“This study is a multi-site RCT comparing the efficacy and cost-effectiveness of manualized MBT-DH and a manualized specialist TAU in the treatment of BPD. The inclusion of patients started in March 2009 and ended in July 2012. The last follow-up measurement, at 36 months, will be in July 2015. Two mental health care centres agreed to participate in this study: Arkin en De Viersprong, both located in Amsterdam. Arkin is a large mental health care centre that specializes in the treatment of BPD. De Viersprong is a national institute for personality problems, offering specialized outpatient, day hospital, and inpatient psychotherapy for adolescent and adult patients with severe personality problems and disorders. Arkin agreed to run four MBT-DH groups and De Viersprong agreed to run two MBT-DH groups in the context of the trial, each consisting of nine patients. The City Crisis Service, which is part of Arkin, agreed to run the specialist TAU condition. The overall aim was to randomize 54 patients to MBT-DH and 54 patients to TAU.”